MDM2 genetic testing is essential for accurately diagnosing left ventricular intimal sarcoma, enabling effective radical resection instead of risky conservative treatment.
MDM2 genetic testing is essential to differentiate aggressive intimal sarcomas from benign cardiac masses when imaging is misleading.
Tasa de eventos absoluta: 0% vs 0%
The classic imaging triad of a calcified, avascular, left-sided cardiac mass can be misleading and in rare cases may mask an aggressive intimal sarcoma. MDM2 genetic testing is critical for definitive diagnosis, guiding lifesaving radical resection over inappropriate and hazardous conservative management.
Ouyang et al. (Tue,) reported a other. MDM2 genetic testing is essential for accurately diagnosing left ventricular intimal sarcoma, enabling effective radical resection instead of risky conservative treatment.